On Demand Pharmaceuticals Announces Preferred Supplier Relationship with Azzur Group

Published on :

On Demand Pharmaceuticals Announces Preferred Supplier Relationship with Azzur Group
NEWS PROVIDED BY
On Demand Pharmaceuticals
Jun 01, 2022, 12:00 ET
SHARE THIS ARTICLE
Building Off Success of Commissioned cGMP Facility
ROCKVILLE, Md., June 1, 2022 /PRNewswire/ — On Demand Pharmaceuticals, Inc. (ODP), an innovative technology company transforming the way medicines are made, announced today that it has signed a Preferred Supplier agreement with Azzur Group through 2024. The transformation of ODP’s Rockville Headquarters into a State-of-the-Art cGMP Medicine Manufacturing facility began with Azzur in the fall of 2020.
Azzur collaborated in designing ODP’s GMP Roadmap and helped develop the strategy and execution plan for ushering in this latest addition to Maryland’s Biotech Hub. Building on the strategy, Azzur worked alongside ODP to initiate a Managed Services approach to execution, providing a single source for Commissioning services, Equipment rentals, Technology subscriptions, and a series of outsourced packages covering Environmental Monitoring, Training, and Documentation.
Dr. John Lewin, ODP’s Chief Medical Officer, said “The flexibility Azzur demonstrated to accommodate the fluid nature of a startup and the challenges we all faced during the COVID-19 pandemic was remarkable. Having the ability to pull on a variety of resources and expertise, when we needed…

Partnering Webinar: Detection of SARS-CoV-2 and other RNA Viruses Using a Novel Improved RT-qPCR Method that Increases Detection Sensitivity and Improves Safety

Published on :

NIH researchers will highlight a novel Covid-19 diagnostic technology from the National Eye Institute (NEI). NEI is seeking partners for collaboration and licensing to accelerate technology development and clinical benefit. [….]

5 Questions with Amy Adams, Executive Director of the Institute for Biohealth Innovation at George Mason University

Published on :

As Executive Director of the Institute for Biohealth Innovation at George Mason University, Amy Adams is responsible for nurturing and advancing biohealth research and innovation interests of more than 250 faculty and thousands of students who represent a broad range of academic disciplines. Her role includes fostering partnerships with industry, healthcare, government, and academic partners.